Li Yan, Xu Jin-kang, Uu Xi-Rorg
Department of Gastroenterology, Kunshan Hospital of Traditional Chinese Medicine, Nanjing University of Traditional Chinese Medicine, Jiangsu.
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2011 Dec;31(12):1635-8.
To study the therapeutic effect of Weiyan serial recipes (WYSR) in treatment of chronic atrophic gastritis (CAG) accompanied with intestinal metaplasia (IM) and/or dysplasia (Dys) and to explore its molecular mechanisms for reversing the gastric precancerous lesions.
One hundred and fifty patients with confirmed diagnosis of CAG accompanied with IM and/or mild Dys were randomly assigned to the treatment group (120 cases) and the control group (30 cases). Patients in the treatment group were respectively treated with WYSR I-IV according to Chinese medicine syndrome typing as incoordination of Gan and Wei syndrome (32 cases), deficiency of Pi and Wei syndrome (35 cases), insufficient Wei-yin syndrome (28 cases), and stasis stagnation in Wei-channel syndrome (25 cases). Patients in the control group orally took Weifuchun Pill. The therapeutic course for all was 3 months, and totally 2 courses. The clinical effects, changes under the gastroscope, the pathological changes, and expressions of gastric mucosal hypoxia-inducible factor-1alpha(HIF-1alpha), vascular endothelial growth factor (VEGF) protein were compared between the two groups before and after treatment.
The total effective rate of the treatment group was 86.7% and the total effective rate of the gastroscopic changes was 78.3%, which was higher than those of the control group (56.7% and 40.0%), showing significant difference (P < 0.01, P < 0.05). The total effective rate of clinical symptoms and that of the pathological changes were higher in the treatment group than in the control group with statistical significance shown (P < 0.05). There was no statistical difference in the expressions of HIF-1alpha and VEGF protein of the control group between before and after treatment (P > 0.05). Compared with before treatment, the post-treatment expressions of HIF-1alpha and VEGF protein both obviously decreased in the treatment group (P < 0.01), and were lower than those in the control group (P < 0.05).
WYSR showed better effects on treating gastric precancerous lesions. It could significantly improve the atrophy, IM, and Dys, and promote the reversal of gastric precancerous lesions. Its mechanisms might possibly be correlated with inhibiting the over-expressions of HIF-1alpha and VEGF protein.
研究胃炎系列方治疗慢性萎缩性胃炎（CAG）伴肠化生（IM）和/或异型增生（Dys）的疗效，并探讨其逆转胃黏膜癌前病变的分子机制。
将150例确诊为CAG伴IM和/或轻度Dys的患者随机分为治疗组（120例）和对照组（30例）。治疗组根据中医辨证分为肝胃不和证（32例）、脾胃虚弱证（35例）、胃阴不足证（28例）、胃络瘀阻证（25例），分别给予胃炎系列方I-IV治疗。对照组口服胃复春片。两组疗程均为3个月，共2个疗程。比较两组治疗前后的临床疗效、胃镜下变化、病理改变及胃黏膜缺氧诱导因子-1α（HIF-1α）、血管内皮生长因子（VEGF）蛋白表达。
治疗组总有效率为86.7%，胃镜变化总有效率为78.3%，均高于对照组（56.7%和40.0%），差异有统计学意义（P<0.01，P<0.05）。治疗组临床症状总有效率和病理改变总有效率均高于对照组，差异有统计学意义（P<0.05）。对照组治疗前后HIF-1α和VEGF蛋白表达差异无统计学意义（P>0.05）。治疗组治疗后HIF-1α和VEGF蛋白表达均明显低于治疗前（P<0.01），且低于对照组（P<0.05）。
胃炎系列方治疗胃黏膜癌前病变疗效较好，能显著改善胃黏膜萎缩、IM及Dys，促进胃黏膜癌前病变的逆转，其机制可能与抑制HIF-1α和VEGF蛋白的过度表达有关。
